TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36313145

Group type: EXPERIMENTAL
Intervention: Orelabrutinib 150 mg orally daily until disease progression or unacceptable toxicity
Number of subjects: 47
Study: 36313720

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced abdominopelvic CT
Number of subjects: 20

Group type: COMPARATOR
Intervention: PET
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 20
Study: 36314021

Group type: EXPERIMENTAL
Intervention: Radiopharmaceutical intervention (specific details not provided)
Number of subjects: 0
Study: 36314033

Group type: EXPERIMENTAL
Intervention: Non-reflective decision assistance strategies based on reminders and decision support tools
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decision information strategies based on knowledge dissemination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reflective decision-making restructuring strategies (audit and feedback with intention formation interventions)
Number of subjects: 0
Study: 36314106

Group type: EXPERIMENTAL
Intervention: Angiotensin Converting Enzyme 2 expressed in lettuce chloroplasts
Number of subjects: 0
Study: 36314131

Group type: EXPERIMENTAL
Intervention: Fatigue cases with emotional distress (moderate-to-severe distress)
Number of subjects: 1023

Group type: COMPARATOR
Intervention: Fatigue cases without emotional distress
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: Fatigue cases differentiated by obesity
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: Fatigue cases differentiated by pain
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: Fatigue cases without emotional distress, obesity, or pain
Number of subjects: 1023
Study: 36314160

Group type: EXPERIMENTAL
Intervention: POC whole-blood hs-cTnI assay (Atellica VTLi) with a threshold of <4 ng/L
Number of subjects: 2572

Group type: EXPERIMENTAL
Intervention: POC whole-blood hs-cTnI assay (Atellica VTLi)
Number of subjects: 2572
Study: 36314198

Group type: EXPERIMENTAL
Intervention: Cannabis inhalation
Number of subjects: 0
Study: 36314507

Group type: EXPERIMENTAL
Intervention: Vertical sleeve gastrectomy (VSG)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Nonsurgical management (Control)
Number of subjects: 66
Study: 36314999

Group type: EXPERIMENTAL
Intervention: First Booster of SARS-COV-2 mRNA Vaccine
Number of subjects: 0
Study: 36315007

Group type: EXPERIMENTAL
Intervention: Pevonedistat with azacitidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36315182

Group type: EXPERIMENTAL
Intervention: Collaboration with hospitals
Number of subjects: 0
Study: 36315224

Group type: EXPERIMENTAL
Intervention: Daily SMS text message reminders to follow their chosen anchoring plan (messages group; treatment group 1)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Daily SMS text messages and incentives conditional on taking their ART medication around the time of their chosen anchor (incentives group; treatment group 2)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 150
Study: 36315223

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36315227

Group type: EXPERIMENTAL
Intervention: Transdiagnostic iCBT
Number of subjects: 200

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 200
Study: 36315231

Group type: EXPERIMENTAL
Intervention: Telepresence Robot (TR) intervention for 12 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 12-week follow-up after TR intervention
Number of subjects: 60
Study: 36315347

Group type: EXPERIMENTAL
Intervention: Sonographer-performed focused vascular ultrasound (FOVUS)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Emergency physician-performed FOVUS
Number of subjects: 326
Study: 36315384

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 27996

Group type: COMPARATOR
Intervention: GLP-1 receptor agonists
Number of subjects: 27996
Study: 36315498

Group type: EXPERIMENTAL
Intervention: Alcohol intervention
Number of subjects: 0
Study: 36315566

Group type: EXPERIMENTAL
Intervention: ENI group (19 patients)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Non ENI group (19 matched patients)
Number of subjects: 358
Study: 36315607

Group type: EXPERIMENTAL
Intervention: Novel Troponin Fragmentation Assay
Number of subjects: 0
Study: 36315921

Group type: EXPERIMENTAL
Intervention: ≥ 2% circulating tumor cells (CTCs)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Assessment of CTCs by multiparameter flow cytometry
Number of subjects: 395
Study: 36316061

Group type: EXPERIMENTAL
Intervention: INCAGN01949 monotherapy (7-1400 mg) in 14-day cycles
Number of subjects: 87
Study: 36316072

Group type: EXPERIMENTAL
Intervention: Standardised follow-up survey after ED disposition
Number of subjects: 1682

Group type: EXPERIMENTAL
Intervention: Prognostic model for biphasic anaphylaxis (BA)
Number of subjects: 1682
Study: 36316081

Group type: EXPERIMENTAL
Intervention: Shared care intervention developed in co-production with users
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 240
Study: 36316115

Group type: EXPERIMENTAL
Intervention: Extended intervention
Number of subjects: 251

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 251
Study: 36316315

Group type: EXPERIMENTAL
Intervention: Viewing 300 of their memory videos during a 3 T fMRI scan
Number of subjects: 23

Group type: COMPARATOR
Intervention: Viewing 300 memory videos from another individual during a 3 T fMRI scan
Number of subjects: 23
Study: 36316335

Group type: EXPERIMENTAL
Intervention: Tetravalent dengue purified inactivated vaccine (DPIV)
Number of subjects: 0
Study: 36316438

Group type: EXPERIMENTAL
Intervention: Positive Surgical Margins (PSM)
Number of subjects: 2166

Group type: COMPARATOR
Intervention: Negative Surgical Margins (NSM)
Number of subjects: 2166
Study: 36316628

Group type: EXPERIMENTAL
Intervention: Oral L-citrulline (150 mg/kg)
Number of subjects: 10
Study: 36316704

Group type: EXPERIMENTAL
Intervention: CNS malaria with AKI
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Hyperpyrexia
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 209
Study: 36316733

Group type: EXPERIMENTAL
Intervention: FPG value (≥ 92 mg/dl) following Italian Diabetes Societies recommendations for COVID 19 pandemic period
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: IADPSG criteria
Number of subjects: 161

Group type: COMPARATOR
Intervention: WHO'99 criteria
Number of subjects: 161
Study: 36316788

Group type: EXPERIMENTAL
Intervention: New child diet quality index calculated from a 28-item dietary questionnaire
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Three 24-hour diet recalls at the 13-month follow-up
Number of subjects: 71
Study: 36316952

Group type: EXPERIMENTAL
Intervention: Multi-cancer early detection test
Number of subjects: 0
Study: 36317012

Group type: EXPERIMENTAL
Intervention: Platelet-mediator concentrate (PMC)
Number of subjects: 0
Study: 36317056

Group type: EXPERIMENTAL
Intervention: Culturally tailored diabetes self-management intervention with group education and race-congruent peer-based phone support.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Culturally tailored diabetes self-management intervention.
Number of subjects: 17
Study: 36317254

Group type: EXPERIMENTAL
Intervention: Regenerative peripheral nerve interfaces and intramuscular electrodes
Number of subjects: 0
Study: 36317421

Group type: EXPERIMENTAL
Intervention: Cluster T1 (n=708) - young, short asthma duration, low prevalence of CRSwNP
Number of subjects: 1263

Group type: EXPERIMENTAL
Intervention: Cluster T2 (n=263) - longest asthma duration
Number of subjects: 1263

Group type: EXPERIMENTAL
Intervention: Cluster T3 (n=292) - older, shortest asthma duration
Number of subjects: 1263

Group type: EXPERIMENTAL
Intervention: Cluster S1 (n=83) - mild-to-moderate asthma, normal lung function
Number of subjects: 1263

Group type: EXPERIMENTAL
Intervention: Cluster S2 (n=53) - severe asthma, longer asthma duration
Number of subjects: 1263

Group type: EXPERIMENTAL
Intervention: Cluster S3 (n=42) - severe asthma, late-onset
Number of subjects: 1263
Study: 36317424

Group type: EXPERIMENTAL
Intervention: Functional impairment (measured using five-dimension EuroQol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multimorbidity (measured by the number of comorbidities)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 0
Study: 36317512

Group type: EXPERIMENTAL
Intervention: Underweight (BMI < 18.5)
Number of subjects: 14688

Group type: EXPERIMENTAL
Intervention: Normal weight (BMI 18.5-24.9)
Number of subjects: 14688

Group type: EXPERIMENTAL
Intervention: Overweight (BMI 25-29.9)
Number of subjects: 14688

Group type: EXPERIMENTAL
Intervention: Obesity (BMI 30-34.9)
Number of subjects: 14688

Group type: EXPERIMENTAL
Intervention: Severe obesity (BMI ≥ 35)
Number of subjects: 14688

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 14688

Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 14688

Group type: EXPERIMENTAL
Intervention: TNM stages I, II, III
Number of subjects: 14688
Study: 36317524

Group type: EXPERIMENTAL
Intervention: Manganese-enhanced magnetic resonance imaging
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (matched volunteers)
Number of subjects: 20
Study: 36317715

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel and pembrolizumab
Number of subjects: 36
Study: 36317867

Group type: EXPERIMENTAL
Intervention: Instructed Group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Uninstructed Group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 36317927

Group type: EXPERIMENTAL
Intervention: rHuEPO (9 IU·kg bw -1 epoetin β)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Saline (0.9% NaCl)
Number of subjects: 48
Study: 36317929

Group type: EXPERIMENTAL
Intervention: Training program for dispatching physicians in geriatric care
Number of subjects: 2671

Group type: EXPERIMENTAL
Intervention: Contact with General Practitioner (GP) in the month preceding the call
Number of subjects: 2671
Study: 36317959

Group type: EXPERIMENTAL
Intervention: Lean CHB-NAFLD patients
Number of subjects: 1226

Group type: COMPARATOR
Intervention: Nonlean CHB-NAFLD patients
Number of subjects: 1226
Study: 36318027

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 187
Study: 36318030

Group type: EXPERIMENTAL
Intervention: In vivo single-voxel diffusion-weighted MR spectroscopy in participants with IS
Number of subjects: 0

Group type: COMPARATOR
Intervention: In vivo single-voxel diffusion-weighted MR spectroscopy in healthy volunteers (HVs)
Number of subjects: 0
Study: 36318233

Group type: EXPERIMENTAL
Intervention: Virtual PConnect program
Number of subjects: 136

Group type: COMPARATOR
Intervention: In-person PConnect program
Number of subjects: 136
Study: 36318307

Group type: EXPERIMENTAL
Intervention: 5 min passive stretching session at 80% of maximal DF angle
Number of subjects: 13
Study: 36318387

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg weekly (qw)
Number of subjects: 2677

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks (q2w)
Number of subjects: 2677

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg (qw or q2w)
Number of subjects: 2677

Group type: EXPERIMENTAL
Intervention: Dupilumab treatment
Number of subjects: 2677
Study: 36318494

Group type: EXPERIMENTAL
Intervention: DSM-5 Level 1 Cross-Cutting Symptom Measure (DSM-XC)
Number of subjects: 3533

Group type: EXPERIMENTAL
Intervention: Bifactor solution of DSM-XC
Number of subjects: 3533
Study: 36318705

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control (abiraterone or enzalutamide)
Number of subjects: 181
Study: 36318879

Group type: EXPERIMENTAL
Intervention: Intravenous dose of 40 IU of vasopressin with epinephrine
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo with epinephrine
Number of subjects: 148
Study: 36319569

Group type: EXPERIMENTAL
Intervention: PAC-SYM
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: PAGI-SYM
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: PAC-QOL
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Straining
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Fullness
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Incomplete bowel movements
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Bloating
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Distension
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Abdominal pain (upper)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Abdominal pain (lower)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Bloating (≥18 vs <18)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Lower abdominal pain (≥18 vs <18)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Stomach fullness (≥18 vs <18)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Abdominal distension (≥18 vs <18)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Treatment dissatisfaction (PAC-QOL)
Number of subjects: 402
Study: 36319717

Group type: EXPERIMENTAL
Intervention: Intratumoral administration of CV8102
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of i.t. CV8102 with systemic anti-PD-1 treatment
Number of subjects: 0
Study: 36319790

Group type: EXPERIMENTAL
Intervention: Natural Orifice Specimen Excision (NOSE)
Number of subjects: 102
Study: 36319877

Group type: EXPERIMENTAL
Intervention: IRT-toolbox (open-access semi-automated segmentation tool)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Manual segmentations
Number of subjects: 10
Study: 36319896

Group type: EXPERIMENTAL
Intervention: CADISS® system
Number of subjects: 15
Study: 36319944

Group type: EXPERIMENTAL
Intervention: STOPP/START-based in-hospital medication review
Number of subjects: 963
Study: 36320022

Group type: EXPERIMENTAL
Intervention: Stimulant medication for ADHD
Number of subjects: 40
Study: 36320050

Group type: EXPERIMENTAL
Intervention: Q-value customized ablation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Wavefront-optimized (WFO) ablation
Number of subjects: 40
Study: 36321279

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention
Number of subjects: 312

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 312
Study: 36321445

Group type: EXPERIMENTAL
Intervention: Device designed to enhance fluid and salt loss via eccrine sweat glands
Number of subjects: 24
Study: 36321601

Group type: EXPERIMENTAL
Intervention: Residual quantitative flow ratio (rQFR) after virtual percutaneous coronary intervention (vPCI)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Post-PCI fractional flow reserve (FFR)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: rQFR ≤0.89
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Target vessel revascularization
Number of subjects: 274
Study: 36321894

Group type: EXPERIMENTAL
Intervention: High-level methanogen microbiota
Number of subjects: 82

Group type: COMPARATOR
Intervention: Low-level methanogen microbiota
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Methanogen levels
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Hydrogenotrophic functional groups
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Copy numbers of genes indicative of total bacteria and acetogens
Number of subjects: 82
Study: 36322113

Group type: EXPERIMENTAL
Intervention: MindShift CBT app plus treatment as usual (TAU) over 6 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 20
Study: 36322396

Group type: EXPERIMENTAL
Intervention: Early Functional Mobilization (EFM)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 47
Study: 36322537

Group type: EXPERIMENTAL
Intervention: MIS-C children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MIS-C children post-recovery (6-9 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other syndromes (non-MIS-C conditions)
Number of subjects: 0
Study: 36322608

Group type: EXPERIMENTAL
Intervention: Depression symptoms
Number of subjects: 1818

Group type: EXPERIMENTAL
Intervention: Patient activation
Number of subjects: 1818
Study: 36322627

Group type: EXPERIMENTAL
Intervention: Regulatory T cells (Tregs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immunosuppressive drugs
Number of subjects: 0
Study: 36322714

Group type: EXPERIMENTAL
Intervention: Bone marrow-derived, allogeneic MSCs (75 million MSCs administered via direct injection, with repeat injection at 3 months if needed)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no MSC therapy)
Number of subjects: 22
Study: 36322782

Group type: EXPERIMENTAL
Intervention: 4-week mobile health (mHealth) prescription to monitor for AF recurrences
Number of subjects: 335
Study: 36322825

Group type: EXPERIMENTAL
Intervention: Dasatinib/prednisone induction followed by blinatumomab/dasatinib postremission therapy for 3 cycles and dasatinib/prednisone maintenance.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Blinatumomab reinduction therapy for patients not achieving response by day 56.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Central nervous system prophylaxis with intrathecal methotrexate for a total of 8 doses.
Number of subjects: 24
Study: 36323235

Group type: EXPERIMENTAL
Intervention: BMS-963272 (MGAT2 inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selective DGAT1 inhibitor
Number of subjects: 0
Study: 36323435

Group type: EXPERIMENTAL
Intervention: Nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) combination therapy
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Quantitative systems pharmacology (QSP) model
Number of subjects: 5000
Study: 36323444

Group type: EXPERIMENTAL
Intervention: Dapagliflozin with standard therapy
Number of subjects: 0
Study: 36323464

Group type: EXPERIMENTAL
Intervention: Maternal antibiotic treatment during pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C-section mode of delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vaginal delivery
Number of subjects: 0
Study: 36323479

Group type: EXPERIMENTAL
Intervention: Maternal pre-pregnancy BMI
Number of subjects: 200
Study: 36323480

Group type: EXPERIMENTAL
Intervention: Higher gestational age
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: Higher socioeconomic status (SES)
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: Older siblings
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: Boys
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: Behavioural difficulties
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: Age interactions
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: Sleep duration, breastfeeding duration, overweight/obesity
Number of subjects: 778
Study: 36323612

Group type: EXPERIMENTAL
Intervention: Afatinib (first-line treatment)
Number of subjects: 152
Study: 36324098

Group type: EXPERIMENTAL
Intervention: Skewed X chromosome inactivation (SXCI)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Androgen receptor (AR) CAG repeats
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: CAG repeat < 20, SXCI, and duration of stimulation
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Ovarian reserve and preimplantation embryo aneuploidy
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Validation cohort of 363 patients with RPL
Number of subjects: 131
Study: 36324132

Group type: EXPERIMENTAL
Intervention: Specialised Paediatric Palliative Care (SPPC) programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine care in a generalised palliative care (PPC) environment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SPPC programme
Number of subjects: 0
Study: 36324191

Group type: EXPERIMENTAL
Intervention: Conservative treatment for trigger finger
Number of subjects: 55
Study: 36324326

Group type: EXPERIMENTAL
Intervention: Pooled-sample testing using the Allplex STI Essential Assay
Number of subjects: 130
Study: 36325355

Group type: EXPERIMENTAL
Intervention: FCR treatment (fludarabine-cyclophosphamide-rituximab)
Number of subjects: 123
Study: 36325385

Group type: EXPERIMENTAL
Intervention: Phased multidimensional intervention bundle
Number of subjects: 297

Group type: COMPARATOR
Intervention: Retrospective control group
Number of subjects: 297
Study: 36325389

Group type: EXPERIMENTAL
Intervention: KIO-100 (PP-001), a small molecule DHODH-inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36325895

Group type: EXPERIMENTAL
Intervention: PCAT attenuation in ACS patients
Number of subjects: 471

Group type: COMPARATOR
Intervention: PCAT attenuation in SAP patients
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Comparison of PCAT attenuation
Number of subjects: 471
Study: 36326077

Group type: EXPERIMENTAL
Intervention: Psychoeducational group programme
Number of subjects: 19
Study: 36326139

Group type: EXPERIMENTAL
Intervention: Maximal voluntary pelvic floor muscle contractions ≥3 (Modified Oxford Scale, scored from 0 to 5)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Diastasis recti abdominis width ≥35 mm
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Diastasis recti abdominis width
Number of subjects: 504
Study: 36326435

Group type: COMPARATOR
Intervention: Avoralstat
Number of subjects: 912

Group type: COMPARATOR
Intervention: Berotralstat
Number of subjects: 912

Group type: COMPARATOR
Intervention: C1-INH (all forms)
Number of subjects: 912

Group type: COMPARATOR
Intervention: Lanadelumab
Number of subjects: 912

Group type: COMPARATOR
Intervention: Danazol
Number of subjects: 912

Group type: COMPARATOR
Intervention: Subcutaneous C1-INH
Number of subjects: 912

Group type: COMPARATOR
Intervention: Plasma-derived C1-INH
Number of subjects: 912

Group type: COMPARATOR
Intervention: Nanofiltered C1-INH
Number of subjects: 912

Group type: COMPARATOR
Intervention: Recombinant human C1-INH
Number of subjects: 912

Group type: COMPARATOR
Intervention: C1-INH (all forms), Berotralstat, Lanadelumab
Number of subjects: 912

Group type: COMPARATOR
Intervention: Adverse events (including serious adverse events)
Number of subjects: 912

Group type: COMPARATOR
Intervention: Mortality
Number of subjects: 912
Study: 36326473

Group type: EXPERIMENTAL
Intervention: Inorganic nitrate/nitrite supplementation for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36326731

Group type: EXPERIMENTAL
Intervention: Immunotherapy (IO)
Number of subjects: 12046

Group type: EXPERIMENTAL
Intervention: Non-immunotherapy systemic anticancer therapies (non-IO)
Number of subjects: 12046

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 12046